{
    "clinical_study": {
        "@rank": "129480", 
        "arm_group": {
            "arm_group_label": "Aloglipin", 
            "description": "Aloglipin 25 mg, tablets, orally, once daily for up to 12 months"
        }, 
        "brief_summary": {
            "textblock": "To examine the safety and efficacy of long-term combination therapy with alogliptin (Nesina)\n      and biguanides in patients with type 2 diabetes mellitus who responded inadequately to\n      treatment with biguanides in addition to diet therapy and exercise therapy."
        }, 
        "brief_title": "Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Surveillance", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of alogliptin  with a 1-year\n      (12-month) observational period, designed to investigate the safety and efficacy of\n      long-term combination therapy with alogliptin and biguanides in patients with type 2\n      diabetes mellitus in the routine clinical setting.\n\n      Participants will be patients with type 2 diabetes mellitus who responded inadequately to\n      treatment with biguanides in addition to diet therapy and exercise therapy. The planned\n      sample size is 1,000.\n\n      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who did not adequately respond to the following treatment \u2022 Treatment with\n             biguanides in addition to diet therapy and exercise therapy\n\n        Exclusion Criteria:\n\n          -  Patients contraindicated for Nesina\n\n               1. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes\n                  mellitus [these patients require prompt adjustment of hyperglycemia by fluid\n                  infusion and insulin, and hence use of Nesina is not appropriate.]\n\n               2. Patients with severe infection, pre- or post-operative patients, or patients\n                  with serious traumatic injury [blood glucose control by insulin injection is\n                  desirable for these patients, and hence use of Nesina is not appropriate.]\n\n               3. Patients with a history of hypersensitivity to any ingredient of Nesina"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with type 2 diabetes mellitus who have been examined at a medical institution"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964976", 
            "org_study_id": "121-014", 
            "secondary_id": "JapicCTI-132282"
        }, 
        "intervention": {
            "arm_group_label": "Aloglipin", 
            "description": "Alogliptin tablets", 
            "intervention_name": "Alogliptin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Nesina", 
                "SYR-322"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Alogliptin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The frequency of adverse events by type, seriousness, time to onset, etc. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
                "measure": "Frequency of Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at month 12 relative to baseline.", 
                "measure": "Change from Baselin in Glycosylated Hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and month 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964976"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change in the value of fasting blood glucose collected at month 12 relative to baseline.", 
            "measure": "Change from Baselin in Fasting blood glucose", 
            "safety_issue": "No", 
            "time_frame": "Baseline and month 12"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}